Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

CNS Medication Trials

Walnut Creek, California

CNS medication trials in Walnut Creek, CA

24 CNS medication studies are recruiting participants at sites in Walnut Creek as of November 17, 2026, according to ClinicalTrials.gov. CNS Medication Trials can help you understand your options and connect with a study team.

Call (888) 927-5768
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Walnut Creek at a glance

  • 24 studies are recruiting at a site in Walnut Creek.
  • By phase: Phase 2 (8), Phase 3 (16).
  • By sponsor: industry (24).
  • By research area: Migraine (9), Depression (8), Schizophrenia (4), ADHD (2), Parkinson's Disease (1).
  • Most recent update to one of these records: November 17, 2026.

Depression studies recruiting in Walnut Creek

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Sunwise Clinical Research
    Registry record
    NCT07573176 · updated
  2. A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Tonix Pharmaceuticals, Inc.
    Registry record
    NCT07621237 · updated
  3. Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07484217 · updated
  4. Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Vanda Pharmaceuticals
    Study site
    Vanda Investigational Site
    Registry record
    NCT06830044 · updated
  5. Brexanolone Lifting Outcomes Of Moms

    • Phase 3
    • Ages 15 to 45
    • Female participants
    Sponsor
    Lipocine Inc.
    Study site
    Lipocine Investigational Site
    Registry record
    NCT07822321 · updated
  6. Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

    • Phase 2
    • Ages 18 to 64
    • All sexes
    Sponsor
    Syndeio Biosciences, Inc
    Study site
    Sunwise Clinical Research LLC
    Registry record
    NCT06547489 · updated
  7. A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    AbbVie
    Study site
    Sunwise Clinical Research /ID# 277555
    Registry record
    NCT07276997 · updated
  8. Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    Autobahn Therapeutics, Inc.
    Study site
    Autobahn Site #126
    Registry record
    NCT06633016 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Walnut Creek, CA on ClinicalTrials.gov.

Schizophrenia studies recruiting in Walnut Creek

  1. A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

    • Phase 2
    • Ages 55 and older
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    Sunwise Clinical Research
    Registry record
    NCT06540833 · updated
  2. A Study of Brenipatide in Adult Participants With Schizophrenia

    • Phase 2
    • Ages 18 to 55
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Sunwise Clinical Research
    Registry record
    NCT07410507 · updated
  3. Randomized Withdrawal Study in Patients With Schizophrenia

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Vanda Pharmaceuticals
    Study site
    Vanda Investigational Site
    Registry record
    NCT06961968 · updated
  4. Study of ALTO-101 in Patients With Schizophrenia

    • Phase 2
    • Ages 21 to 55
    • All sexes
    Sponsor
    Alto Neuroscience
    Registry record
    NCT06502964 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Walnut Creek, CA on ClinicalTrials.gov.

ADHD studies recruiting in Walnut Creek

  1. Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)

    • Phase 3
    • Ages 6 to 11
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07717879 · updated
  2. Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07717892 · updated

Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Walnut Creek, CA on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Walnut Creek

  1. A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    John Muir Health Cancer Center ( Site 6028)
    Registry record
    NCT06952504 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Walnut Creek, CA on ClinicalTrials.gov.

Migraine studies recruiting in Walnut Creek

  1. Study of EVO756 in Adults With Migraine

    • Phase 2
    • Ages 18 to 64
    • All sexes
    Sponsor
    Evommune, Inc.
    Study site
    Diablo Clinical Research dba Flourish Research
    Registry record
    NCT07616128 · updated
  2. A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study sites
    Diablo Clinical Research · Sunwise Clinical Research
    Registry record
    NCT07645924 · updated
  3. A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study sites
    Diablo Clinical Research · Sunwise Clinical Research
    Registry record
    NCT07674654 · updated
  4. Randomized Study in Children and Adolescents With Migraine: Acute Treatment

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Study site
    Sunwise Clinical Research
    Registry record
    NCT04649242 · updated
  5. Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Study site
    Sunwise Clinical Research
    Registry record
    NCT04743141 · updated
  6. A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    AbbVie
    Study site
    Sunwise Clinical Research /ID# 270431
    Registry record
    NCT06810505 · updated
  7. A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    AbbVie
    Study site
    Sunwise Clinical Research /ID# 248529
    Registry record
    NCT05711394 · updated
  8. Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    AbbVie
    Study site
    Sunwise Clinical Research /ID# 230971
    Registry record
    NCT05125302 · updated
  9. A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

    • Phase 3
    • Ages 18 to 45
    • Female participants
    Sponsor
    Pfizer
    Study site
    Diablo Clinical Research, Inc.
    Registry record
    NCT06641466 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Walnut Creek, CA on ClinicalTrials.gov.

Ask about studies near Walnut Creek

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in California

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5768

or send a short form

How should we reach you?

Call